Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 28, 2015 5:26 AM ET


Company Overview of Pharnext SAS

Company Overview

Pharnext SAS, a biopharmaceutical company, engages in the development of treatments for severe neurological diseases. The company specializes in drug repositioning. Its target pathologies include Charcot-Marie-Tooth disease; and diabetic and toxic peripheral neuropathies, as well as severe neurodegenerative diseases in general and peripheral neuropathies. The company was founded in 2007 and is based in Paris, France.

Pépinière Santé Cochin

29 rue du Faubourg Saint Jacques

Paris,  75014


Founded in 2007


33 1 55 42 62 00


33 1 55 42 62 01

Key Executives for Pharnext SAS

Co-Founder, Chairman and Chief Executive Officer
Age: 62
Co-Founder and Administrative & Financial Director
Co-Founder and Data Mining Officer
Co-founder and Biology Officer
Co-Founder and Chief Scientific Officer
Compensation as of Fiscal Year 2015.

Pharnext SAS Key Developments

Pharnext SAS Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Pharnext SAS Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Pharnext SAS Announces Nomination of Michel de Rosen to its Board of Directors

Pharnext SAS announced the nomination of Michel de Rosen to its board of directors. The wealth of expertise Michel de Rosen has cultivated during his time as an executive in the pharmaceutical and biotechnology industries will be an asset to Pharnext moving forward. For nearly 25 years, Michel de Rosen held various executive positions at Rhone-Poulenc, in particular in its pharmaceutical subsidiary Rhone-Poulenc Rorer, now known as Sanofi, and then at ViroPharma.

Ipsen Joins Pharnext's Board of Directors

Pharnext announced that Ipsen has joined its Board of Directors. Ipsen will be represented on Pharnext's board of directors by Marc de Garidel, CEO.

Similar Private Companies By Industry

Company Name Region
MSD France SAS Europe
Laboratoire Tetra Medical Europe
Sogeval S.A. Europe
Laboratoire Medix Europe
Laboratoire IPRAD SAS Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Pharnext SAS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at